Pharmaceutical Preparations Industry - SEC Form 4 Insider Trading Screener
Manufacturing Sector - Chemicals - Pharmaceutical Preparations
100 results - 
- 
- 
- 
- 
- 
- 
- - - - - - | TC | cnt | 1d | 1w | 1m | 6m |
X |
Filing Date |
Trade Date |
Ticker |
Company | Insider Name | Insider Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2018-09-12 | XBIT | Xbiotech Inc. | McKenzie W Thorpe | Dir, 10% | S - Sale | $3.07 | -49,584 | 3,912,734 | -1% | -$152,095 | |||||
| M | 2018-09-13 | VTL | Vital Therapies Inc | Satter Muneer A | Dir, 10% | S - Sale | $0.36 | -11,382,277 | 0 | -100% | -$4,145,637 | |||||
2018-09-13 | VTL | Vital Therapies Inc | Hasnain Faheem | Dir | S - Sale | $0.44 | -177,443 | 8,000 | -96% | -$77,679 | ||||||
2018-09-13 | VTL | Vital Therapies Inc | Bienaime Jean Jacques | Dir | S - Sale | $0.47 | -20,000 | 45,119 | -31% | -$9,400 | ||||||
| D | 2018-09-13 | BMRN | Biomarin Pharmaceutical Inc | Meier Richard A | Dir | S - Sale+OE | $99.24 | -3,000 | 81,610 | -4% | -$297,722 | |||||
| DM | 2018-09-11 | PKTX | Protokinetix, Inc. | Smith Clarence Edward | Pres, CEO, 10% | P - Purchase | $0.12 | +150,000 | 63,617,302 | 0% | +$17,988 | |||||
2018-09-13 | BMRN | Biomarin Pharmaceutical Inc | Davis George Eric | EVP, GC | S - Sale | $99.57 | -12,000 | 74,950 | -14% | -$1,194,840 | ||||||
2018-09-14 | JAZZ | Jazz Pharmaceuticals Plc | Miller Michael Patrick | EVP, US Commercial | S - Sale | $165.20 | -200 | 25,372 | -1% | -$33,040 | ||||||
| D | 2018-09-14 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale+OE | $18.78 | -15,776 | 27,042 | -37% | -$296,336 | |||||
| M | 2018-09-13 | ATHX | Athersys, Inc / New | Harrington John J | Exec Vice Pres, CSO | S - Sale | $1.91 | -15,000 | 667,770 | -2% | -$28,707 | |||||
| M | 2018-09-13 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $1.20 | +210,000 | 7,386,163 | +3% | +$252,354 | |||||
| M | 2018-09-13 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $1.20 | +210,000 | 7,386,163 | +3% | +$252,354 | |||||
| M | 2018-09-13 | NERV | Minerva Neurosciences, Inc. | Doyle William F | Dir | P - Purchase | $10.50 | +2,200 | 10,211 | +27% | +$23,100 | |||||
2018-09-13 | BHC | Bausch Health Companies Inc. | De Schutter Richard U | Dir | P - Purchase | $23.96 | +125,000 | 269,727 | +86% | +$2,995,000 | ||||||
2018-09-14 | BHC | Bausch Health Companies Inc. | Herendeen Paul | EVP, CFO | P - Purchase | $22.61 | +10,000 | 226,866 | +5% | +$226,100 | ||||||
2018-09-14 | BHC | Bausch Health Companies Inc. | Papa Joseph C | COB, CEO | P - Purchase | $22.32 | +30,000 | 687,077 | +5% | +$669,600 | ||||||
2018-09-13 | CTLT | Catalent, Inc. | Morel Donald E Jr | Dir | P - Purchase | $43.00 | +10,000 | 36,958 | +37% | +$430,000 | ||||||
2018-09-13 | FOLD | Amicus Therapeutics Inc | Perceptive Advisors LLC | 10% | P - Purchase | $11.74 | +100,000 | 20,624,424 | 0% | +$1,174,000 | ||||||
| D | 2018-09-12 | PAHC | Phibro Animal Health Corp | Bfi Co., LLC | 10% | S - Sale+OE | $45.04 | -520 | 59,480 | -1% | -$23,421 | |||||
| D | 2018-09-12 | PAHC | Phibro Animal Health Corp | Bendheim Daniel M | EVP, Corporate Strategy | S - Sale+OE | $44.30 | -2,500 | 0 | -100% | -$110,750 | |||||
| D | 2018-09-12 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $45.04 | -520 | 59,480 | -1% | -$23,421 | |||||
| DM | 2018-09-12 | TXMD | Therapeuticsmd, Inc. | Bernick Brian | Dir | S - Sale+OE | $6.30 | -182,800 | 6,802,371 | -3% | -$1,151,640 | |||||
2018-09-13 | ADRO | Aduro Biotech, Inc. | Templeman Blaine | EVP, GC | S - Sale | $6.50 | -6,056 | 141,381 | -4% | -$39,360 | ||||||
2018-09-13 | ADRO | Aduro Biotech, Inc. | Van Elsas Andrea | Chief Scientific Officer | S - Sale | $6.50 | -9,754 | 264,286 | -4% | -$63,394 | ||||||
2018-09-13 | ADRO | Aduro Biotech, Inc. | Lew Jennifer | CFO | S - Sale | $6.50 | -5,623 | 136,190 | -4% | -$36,546 | ||||||
2018-09-13 | ADRO | Aduro Biotech, Inc. | Sacks Natalie | Chief Medical Officer | S - Sale | $6.50 | -3,028 | 173,720 | -2% | -$19,680 | ||||||
2018-09-13 | ADRO | Aduro Biotech, Inc. | Isaacs Stephen T | Pres, CEO | S - Sale | $6.50 | -24,143 | 341,785 | -7% | -$156,913 | ||||||
2018-09-14 | INNT | Innovate Biopharmaceuticals, Inc. | Prior Christopher P. | CEO | P - Purchase | $5.82 | +200 | 2,009 | +11% | +$1,164 | ||||||
| DM | 2018-09-12 | LOXO | Loxo Oncology, Inc. | Burstein Jennifer | SVP of Finance | S - Sale+OE | $166.96 | -2,500 | 0 | -100% | -$417,392 | |||||
| DM | 2018-09-12 | LOXO | Loxo Oncology, Inc. | Bilenker Joshua H. | Pres, CEO | S - Sale+OE | $166.20 | -20,000 | 165,407 | -11% | -$3,323,965 | |||||
| DM | 2018-09-12 | LOXO | Loxo Oncology, Inc. | Van Naarden Jacob | Chief Business Officer | S - Sale+OE | $166.32 | -10,000 | 13,700 | -42% | -$1,663,179 | |||||
| DM | 2018-09-12 | BDSI | Biodelivery Sciences International Inc | Odonnell Francis E Jr | Dir | S - Sale+OE | $2.84 | -151,039 | 538,187 | -22% | -$428,284 | |||||
| D | 2018-09-12 | RSPI | Respirerx Pharmaceuticals Inc. | Lippa Arnold | Exec COB, CSO | P - Purchase | $0.00 | +47,620 | 0 | -100% | +$0 | |||||
| D | 2018-09-13 | FGEN | Fibrogen Inc | Cotroneo Pat | SVP, Finance, CFO | S - Sale+OE | $59.50 | -2,318 | 228,604 | -1% | -$137,921 | |||||
2018-09-12 | TBPH | Theravance Biopharma, Inc. | Worboys Philip D | SVP, Translational Science | S - Sale | $28.50 | -6,393 | 166,753 | -4% | -$182,201 | ||||||
2018-09-12 | VTL | Vital Therapies Inc | Cohen Cheryl | Dir | S - Sale | $0.55 | -3,500 | 0 | -100% | -$1,925 | ||||||
| M | 2018-09-12 | ZYME | Zymeworks Inc. | Lilly Eli & Co | 10% | S - Sale | $14.49 | -30,959 | 3,873,418 | -1% | -$448,463 | |||||
| M | 2018-09-10 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.04 | +7,000 | 25,916,798 | 0% | +$273 | |||||
2018-09-11 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB, CEO, 10% | P - Purchase | $0.33 | +1,000 | 5,918,497 | 0% | +$330 | ||||||
2018-09-12 | FOLD | Amicus Therapeutics Inc | Perceptive Advisors LLC | 10% | P - Purchase | $12.00 | +500,000 | 20,524,424 | +2% | +$6,001,500 | ||||||
| D | 2018-09-13 | GERN | Geron Corp | Spiegel Robert J. | Dir | S - Sale+OE | $6.85 | -175,000 | 65,576 | -73% | -$1,198,750 | |||||
| M | 2018-09-11 | NVUS | Novus Therapeutics, Inc. | Turkel Catherine C. | Pres | P - Purchase | $4.78 | +33,680 | 79,004 | +74% | +$161,147 | |||||
2018-09-12 | INNT | Innovate Biopharmaceuticals, Inc. | Prior Christopher P. | CEO | P - Purchase | $6.13 | +500 | 1,809 | +38% | +$3,065 | ||||||
| D | 2018-09-11 | ADXS | Advaxis, Inc. | Appel Roni | Dir | P - Purchase | $1.20 | +33,333 | 157,143 | +27% | +$40,000 | |||||
2018-09-11 | PFNX | Pfenex Inc. | Schimmelpennink Evert B. | See Remarks | P - Purchase | $5.04 | +10,000 | 26,658 | +60% | +$50,385 | ||||||
2018-09-11 | PFNX | Pfenex Inc. | Schneider Phillip M | Dir | P - Purchase | $4.99 | +11,000 | 11,000 | New | +$54,890 | ||||||
| M | 2018-09-11 | AGIO | Agios Pharmaceuticals Inc | Maraganore John | Dir | S - Sale | $72.23 | -27,717 | 22,047 | -56% | -$2,002,110 | |||||
| M | 2018-09-10 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $1.18 | +475,000 | 7,176,163 | +7% | +$558,393 | |||||
| M | 2018-09-10 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $1.18 | +475,000 | 7,176,163 | +7% | +$558,393 | |||||
| DM | 2018-09-10 | TXMD | Therapeuticsmd, Inc. | Milligan John C.K. IV | Pres, Secretary | S - Sale+OE | $6.10 | -250,000 | 5,464,606 | -4% | -$1,523,875 | |||||
| M | 2018-09-10 | RIGL | Rigel Pharmaceuticals Inc | Mayer Eldon C. III | EVP, Chief Commercial Officer | P - Purchase | $3.26 | +100,000 | 215,000 | +87% | +$325,550 | |||||
2018-09-10 | KALV | Kalvista Pharmaceuticals, Inc. | Oronsky Arnold L | Dir | P - Purchase | $17.00 | +58,824 | 388,766 | +18% | +$1,000,008 | ||||||
2018-09-10 | KALV | Kalvista Pharmaceuticals, Inc. | Cha Albert | Dir | P - Purchase | $17.00 | +1,058,824 | 1,359,149 | +353% | +$18,000,008 | ||||||
2018-09-10 | FGEN | Fibrogen Inc | Cotroneo Pat | SVP, Finance, CFO | S - Sale | $57.35 | -1,011 | 220,422 | 0% | -$57,981 | ||||||
| D | 2018-09-10 | FGEN | Fibrogen Inc | Routti Jorma | Dir | S - Sale+OE | $57.31 | -6,000 | 131,540 | -4% | -$343,837 | |||||
| M | 2018-09-10 | ZYME | Zymeworks Inc. | Lilly Eli & Co | 10% | S - Sale | $14.75 | -15,777 | 3,904,377 | 0% | -$232,669 | |||||
2018-09-12 | HRTX | Heron Therapeutics, Inc. /de/ | Tang Kevin C | Dir, 10% | S - Sale | $35.75 | -2,695,000 | 5,851,503 | -32% | -$96,346,250 | ||||||
| M | 2018-09-10 | BSTC | Biospecifics Technologies Corp | Wegman Mark N | Dir | S - Sale | $57.52 | -6,500 | 65,272 | -9% | -$373,861 | |||||
| M | 2018-09-10 | NERV | Minerva Neurosciences, Inc. | Doyle William F | Dir | P - Purchase | $9.80 | +8,011 | 8,011 | New | +$78,507 | |||||
| D | 2018-09-10 | KPTI | Karyopharm Therapeutics Inc. | Primiano Christopher Brett | EVP, CBO, GC, Secretary | S - Sale+OE | $18.90 | -10,000 | 2,881 | -78% | -$189,046 | |||||
| M | 2018-09-07 | XBIT | Xbiotech Inc. | McKenzie W Thorpe | Dir, 10% | S - Sale | $3.31 | -29,603 | 3,962,318 | -1% | -$98,097 | |||||
2018-09-10 | IMGN | Immunogen Inc | Berkenblit Anna | VP, Chief Medical Officer | S - Sale | $9.46 | -5,851 | 138,620 | -4% | -$55,350 | ||||||
2018-09-07 | MCRB | Seres Therapeutics, Inc. | Pomerantz Roger | Pres, CEO | S - Sale | $9.00 | -1,810 | 213,976 | -1% | -$16,291 | ||||||
| D | 2018-09-07 | CORT | Corcept Therapeutics Inc | Fishman Robert S | Chief Medical Officer | S - Sale+OE | $14.57 | -8,000 | 0 | -100% | -$116,533 | |||||
| D | 2018-09-10 | TEVA | Teva Pharmaceutical Industries Ltd | Daniell Richard | EVP, European Commercial | S - Sale+OE | $21.25 | -696 | 0 | -100% | -$14,790 | |||||
| M | 2018-09-07 | GALT | Galectin Therapeutics Inc | Omenn Gilbert S | Dir | S - Sale | $6.02 | -19,370 | 48,191 | -29% | -$116,585 | |||||
2018-09-07 | JNJ | Johnson & Johnson | Kapusta Ronald A | Controller, CAO | S - Sale | $137.18 | -7,899 | 26,485 | -23% | -$1,083,607 | ||||||
2018-09-07 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.04 | +15,600 | 25,909,798 | 0% | +$599 | ||||||
| DM | 2018-09-06 | TXMD | Therapeuticsmd, Inc. | Finizio Robert G | CEO, 10% | S - Sale+OE | $6.24 | -184,000 | 20,393,559 | -1% | -$1,147,240 | |||||
| D | 2018-09-06 | ARWR | Arrowhead Pharmaceuticals, Inc. | Myszkowski Kenneth Allen | CFO | S - Sale+OE | $19.34 | -45,000 | 310,815 | -13% | -$870,200 | |||||
2018-09-07 | INNT | Innovate Biopharmaceuticals, Inc. | Laumas Sandeep | Exec COB | P - Purchase | $6.10 | +500 | 760,373 | 0% | +$3,050 | ||||||
| D | 2018-09-06 | VTVT | Vtv Therapeutics Inc. | Perelman Ronald O | 10% | P - Purchase | $1.33 | +1,879,699 | 6,778,470 | +38% | +$2,500,000 | |||||
2018-09-06 | REGN | Regeneron Pharmaceuticals Inc | Sanofi | 10% | S - Sale | $406.68 | -104,552 | 23,654,384 | 0% | -$42,519,249 | ||||||
| D | 2018-09-07 | KPTI | Karyopharm Therapeutics Inc. | Kauffman Michael | CEO | S - Sale+OE | $19.31 | -12,500 | 1,320,271 | -1% | -$241,384 | |||||
| D | 2018-09-07 | KPTI | Karyopharm Therapeutics Inc. | Shacham Sharon | Pres, CSO | S - Sale+OE | $19.31 | -12,500 | 1,320,271 | -1% | -$241,384 | |||||
2018-09-10 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale | $119.00 | -810 | 1,555 | -34% | -$96,390 | ||||||
2018-09-06 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.04 | +1,000 | 25,894,198 | 0% | +$40 | ||||||
| M | 2018-09-05 | ENDV | Endonovo Therapeutics, Inc. | Mann Michael Scott | Pres, 10% | P - Purchase | $0.04 | +38,000 | 25,893,198 | 0% | +$1,685 | |||||
2018-08-23 | AMAR | Amarillo Biosciences Inc | Chen Stephen T | Pres,COB, CEO, 10% | P - Purchase | $0.35 | +1,000 | 5,917,497 | 0% | +$350 | ||||||
2018-09-07 | LLY | Lilly Eli & Co | Lilly Endowment Inc | 10% | S - Sale | $106.76 | -180,000 | 119,790,804 | 0% | -$19,217,055 | ||||||
2018-09-06 | SCYX | Scynexis Inc | Angulo Gonzalez David | Chief Medical Officer | P - Purchase | $1.27 | +7,000 | 108,790 | +7% | +$8,890 | ||||||
2018-09-07 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $5.57 | +10,000 | 191,757,326 | 0% | +$55,705 | ||||||
2018-09-07 | OPK | Opko Health, Inc. | Fishel Robert Scott | Dir | P - Purchase | $4.63 | +10,000 | 4,070,728 | 0% | +$46,300 | ||||||
2018-09-05 | NVUS | Novus Therapeutics, Inc. | Turkel Catherine C. | Pres | P - Purchase | $3.97 | +805 | 45,324 | +2% | +$3,193 | ||||||
| DM | 2018-09-06 | FGEN | Fibrogen Inc | Neff Thomas B | CEO | S - Sale+OE | $57.51 | -39,636 | 2,913,326 | -1% | -$2,279,500 | |||||
| M | 2018-09-05 | KPTI | Karyopharm Therapeutics Inc. | Chione Ltd | 10% | S - Sale | $21.05 | -164,800 | 7,631,267 | -2% | -$3,468,730 | |||||
2018-09-05 | ICPT | Intercept Pharmaceuticals, Inc. | Shapiro David | Chief Medical Officer | S - Sale | $111.43 | -4,917 | 42,196 | -10% | -$547,891 | ||||||
| M | 2018-09-05 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $0.86 | +160,000 | 6,701,163 | +2% | +$138,162 | |||||
| M | 2018-09-05 | BLPH | Bellerophon Therapeutics, Inc. | Venrock Associates IV L P | 10% | P - Purchase | $0.86 | +160,000 | 6,701,163 | +2% | +$138,162 | |||||
2018-09-07 | BSTC | Biospecifics Technologies Corp | Gitman Paul | Dir | S - Sale | $57.64 | -1,000 | 20,000 | -5% | -$57,637 | ||||||
| D | 2018-08-30 | STDY | Steadymed Ltd. | Orbimed Advisors LLC | 10% | S - Sale+OE | $4.46 | -4,246,196 | 0 | -100% | -$18,938,034 | |||||
| M | 2018-09-05 | ASMB | Assembly Biosciences, Inc. | Lopatin Uri A | Chief Med. Officer, VP Res. De | S - Sale | $40.09 | -15,540 | 618,611 | -2% | -$622,989 | |||||
| D | 2018-09-06 | JAZZ | Jazz Pharmaceuticals Plc | Enright Patrick G | Dir | S - Sale+OE | $168.76 | -10,130 | 16,469 | -38% | -$1,709,565 | |||||
| D | 2018-09-06 | ATNX | Athenex, Inc. | Wu Jinn | Dir | P - Purchase | $16.09 | +2,500 | 266,708 | +1% | +$40,220 | |||||
| D | 2018-09-05 | AGIO | Agios Pharmaceuticals Inc | Alenson Carman | Principal Accounting Officer | S - Sale+OE | $83.00 | -312 | 152 | -67% | -$25,896 | |||||
| D | 2018-09-06 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $118.00 | -810 | 2,365 | -26% | -$95,580 | |||||
| D | 2018-09-05 | AGIO | Agios Pharmaceuticals Inc | Biller Scott | Chief Scientific Officer | S - Sale+OE | $83.07 | -3,000 | 57,196 | -5% | -$249,215 | |||||
2018-09-06 | CYTK | Cytokinetics Inc | Malik Fady Ibraham | EVP Research, Development | S - Sale | $8.00 | -1,500 | 91,567 | -2% | -$12,000 | ||||||
2018-09-05 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $7.94 | -4,000 | 168,188 | -2% | -$31,769 | ||||||
2018-09-05 | SYBX | Synlogic, Inc. | Miller Paul Francis | Chief Scientific Officer | S - Sale | $12.55 | -3,000 | 63,135 | -5% | -$37,635 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |